Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058643 | 0.88 | KDM4E (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL31058646 | 0.86 | KDM4E (0.49) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL30811130 | 0.86 | ACE (0.49) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9324856 | 0.86 | KDM4E (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL6661780 | 0.86 | KDM4E (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL6661779 | 0.86 | KDM4E (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL5060887 | 0.84 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL930021 | 0.84 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL522713 | 0.84 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL121965 | 0.84 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | claimed |
| CN-114470224-A | Acid-sensitive polypeptide liposome, preparation method and application thereof in mRNA drug delivery | 深圳深创生物药业有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250082717-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | RHYTHM PHARMACEUTICALS INC (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| EP-4029513-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION | Rhythm Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114470224-A | Acid-sensitive polypeptide liposome, preparation method and application thereof in mRNA drug delivery | 深圳深创生物药业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114470224-A | Acid-sensitive polypeptide liposome, preparation method and application thereof in mRNA drug delivery | 深圳深创生物药业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082717-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | MC4R, MC2R, MC5R | MAPT 2674/4885KDM4E 1715/4885THRB 193/4885 |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | MAPT 2929/4885KDM4E 1687/4885THRB 320/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | MAPT 1236/4885KDM4E 328/4885THRB 160/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | MAPT 3005/4885KDM4E 4248/4885THRB 65/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | MAPT 2929/4885KDM4E 1687/4885THRB 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.